Clinical Trial Update: Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating idelalisib (GS-1101) with rituximab in previously treated indolent non-Hodgkin lymphoma was terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Indolent Non-Hodgkin's Lymphomas | Phase 3 | Status: TERMINATED | Results posted: 2017-05-11